• Plasma α-ketoglutaric acid was consistently elevated both before and at the onset of cGVHD in children and adolescents.

  • Metabolomics profiling of a large pediatric cohort found distinctive patterns in cGVHD, late aGVHD, and clinical presentations of cGVHD.

Chronic graft-versus-host disease (cGVHD) is the most common cause for non-relapse mortality postallogeneic hematopoietic stem cell transplant (HSCT). However, there are no well-defined biomarkers for cGVHD or late acute GVHD (aGVHD). This study is a longitudinal evaluation of metabolomic patterns of cGVHD and late aGVHD in pediatric HSCT recipients. A quantitative analysis of plasma metabolites was performed on 222 evaluable pediatric subjects from the ABLE/PBMTC1202 study. We performed a risk-assignment analysis at day + 100 (D100) on subjects who later developed either cGVHD or late aGVHD after day 114 to non-cGVHD controls. A second analysis at diagnosis used fixed and mixed multiple regression to compare cGVHD at onset to time-matched non-cGVHD controls. A metabolomic biomarker was considered biologically relevant only if it met all 3 selection criteria: (1) P ≤ .05; (2) effect ratio of ≥1.3 or ≤0.75; and (3) receiver operator characteristic AUC ≥0.60. We found a consistent elevation in plasma α-ketoglutaric acid before (D100) and at the onset of cGVHD, not impacted by cGVHD severity, pubertal status, or previous aGVHD. In addition, late aGVHD had a unique metabolomic pattern at D100 compared with cGVHD. Additional metabolomic correlation patterns were seen with the clinical presentation of pulmonary, de novo, and progressive cGVHD. α-ketoglutaric acid emerged as the single most significant metabolite associated with cGVHD, both in the D100 risk-assignment and later diagnostic onset analysis. These distinctive metabolic patterns may lead to improved subclassification of cGVHD. Future validation of these exploratory results is needed. This trial was registered at www.clinicaltrials.gov as #NCT02067832.

1.
Arai
S
,
Arora
M
,
Wang
T
, et al;
Graft-vs-Host Disease Working Committee of the CIBMTR
.
Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research
.
Biol Blood Marrow Transplant.
2015
;
21
(
2
):
266
-
274
.
2.
Arora
M
,
Cutler
CS
,
Jagasia
MH
, et al
.
Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation
.
Biol Blood Marrow Transplant.
2016
;
22
(
3
):
449
-
455
.
3.
Bhatia
S
,
Francisco
L
,
Carter
A
, et al
.
Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study
.
Blood.
2007
;
110
(
10
):
3784
-
3792
.
4.
Boyiadzis
M
,
Arora
M
,
Klein
JP
, et al
.
Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia
.
Clin Cancer Res.
2014
;
21
(
9
):
2020
-
2028
.
5.
Schultz
KR
,
Kariminia
A
,
Ng
B
, et al
.
Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies
.
Blood.
2020
;
135
(
15
):
1287
-
1298
.
6.
Wolff
D
,
Greinix
H
,
Lee
SJ
, et al
.
Biomarkers in chronic graft-versus-host disease: quo vadis?
Bone Marrow Transplant.
2018
;
53
(
7
):
832
-
837
.
7.
Johnson
CH
,
Ivanisevic
J
,
Siuzdak
G.
Metabolomics: beyond biomarkers and towards mechanisms
.
Nat Rev Mol Cell Biol.
2016
;
17
(
7
):
451
-
459
.
8.
Xia
J
,
Broadhurst
DI
,
Wilson
M
,
Wishart
DS.
Translational biomarker discovery in clinical metabolomics: an introductory tutorial
.
Metabolomics.
2012
;
9
(
2
):
280
-
299
.
9.
Lynch Kelly
D
,
Farhadfar
N
,
Starkweather
A
, et al
.
Global metabolomics in allogeneic hematopoietic cell transplantation recipients discordant for chronic graft-versus-host disease
.
Biol Blood Marrow Transplant.
2020
;
26
(
10
):
1803
-
1810
.
10.
Alborghetti
MR
,
Correa
MEP
,
Whangbo
J
, et al
.
Clinical metabolomics identifies blood serum branched chain amino acids as potential predictive biomarkers for chronic graft vs. host disease
.
Front Oncol.
2019
;
9
:
141
.
11.
Markey
KA
,
Schluter
J
,
Gomes
ALC
, et al
.
The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD
.
Blood.
2020
;
136
(
1
):
130
-
136
.
12.
Cuvelier
GDE
,
Nemecek
ER
,
Wahlstrom
JT
, et al
.
Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria
.
Blood.
2019
;
134
(
3
):
304
-
316
.
13.
Filipovich
AH
,
Weisdorf
D
,
Pavletic
S
, et al
.
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
.
Biol Blood Marrow Transplant.
2005
;
11
(
12
):
945
-
956
.
14.
Foroutan
A
,
Guo
AC
,
Vazquez-Fresno
R
, et al
.
Chemical composition of commercial cow’s milk
.
J Agric Food Chem.
2019
;
67
(
17
):
4897
-
4914
.
15.
Foroutan
A
,
Fitzsimmons
C
,
Mandal
R
, et al
.
The bovine metabolome
.
Metabolites.
2020
;
10
(
6
):
233
.
16.
Cuvelier
GDE
,
Li
A
,
Drissler
S
, et al
.
Age related differences in the biology of chronic graft-versus-host disease after hematopoietic stem cell transplantation
.
Front Immunol.
2020
;
11
:
571884
.
17.
Fujii
H
,
Cuvelier
G
,
She
K
, et al
.
Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children’s Oncology Group
.
Blood.
2008
;
111
(
6
):
3276
-
3285
.
18.
Jagasia
MH
,
Greinix
HT
,
Arora
M
, et al
.
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report
.
Biol Blood Marrow Transplant.
2015
;
21
(
3
):
389
-
401.e1
.
19.
Kariminia
A
,
Holtan
SG
,
Ivison
S
, et al
.
Heterogeneity of chronic graft-versus-host disease biomarkers: the only consistent association is with CXCL10 and CXCR3+ NK cells
.
Blood.
2016
;
127
(
24
):
3082
-
3091
.
20.
Zdzisińska
B
,
Żurek
A
,
Kandefer-Szerszeń
M.
Alpha-Ketoglutarate as a molecule with pleiotropic activity: well-known and novel possibilities of therapeutic use
.
Arch Immunol Ther Exp.
2016
;
65
(
1
):
21
-
36
.
21.
Ge
J
,
Cui
H
,
Xie
N
, et al
.
Glutaminolysis promotes collagen translation and stability via α-Ketoglutarate-mediated mTOR activation and proline hydroxylation
.
Am J Respir Cell Mol Biol.
2018
;
58
(
3
):
378
-
390
.
22.
Tijaro-Ovalle
NM
,
Karantanos
T
,
Wang
H-T
,
Boussiotis
VA.
Metabolic targets for improvement of allogeneic hematopoietic stem cell transplantation and graft-vs.-host disease
.
Front Immunol.
2019
;
10
:
295
.
23.
Nguyen
HD
,
Kuril
S
,
Bastian
D
,
Yu
X-Z.
T-cell metabolism in hematopoietic cell transplantation
.
Front Immunol.
2018
;
9
:
176
.
24.
Kumari
R
,
Palaniyandi
S
,
Hildebrandt
GC.
Metabolic reprogramming – a new era how to prevent and treat graft versus host disease after allogeneic hematopoietic stem cell transplantation has begun
.
Front Pharmacol.
2020
;
11
:
588449
.
25.
Zasłona
Z
,
O’Neill
LAJ.
Cytokine-like roles for metabolites in immunity
.
Mol Cell.
2020
;
78
(
5
):
814
-
823
.
26.
Puleston
DJ
,
Baixauli
FC
,
Sanin
DE
, et al
.
Polyamine metabolism is a central determinant of helper T cell lineage fidelity
.
Cell Metab.
2019
;
30
(
2
):
352
-
363
.
27.
Jasperson
LK
,
Bucher
C
,
Panoskaltsis-Mortari
A
, et al
.
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality
.
Blood.
2008
;
111
(
6
):
3257
-
3265
.
28.
Nguyen
HD
,
Chatterjee
S
,
Haarberg
KM
, et al
.
Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation
.
J Clin Invest.
2016
;
126
(
4
):
1337
-
1352
.
29.
Yan
F
,
Wen
Z
,
Wang
R
, et al
.
Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics
.
BMC Pulm Med.
2017
;
17
(
1
):
174
.
30.
Tan
Y
,
Jia
D
,
Lin
Z
, et al
.
Potential metabolic biomarkers to identify interstitial lung abnormalities
.
Int J Mol Sci.
2016
;
17
(
7
):
1148
.
31.
Suryadevara
V
,
Ramchandran
R
,
Kamp
DW
,
Natarajan
V.
Lipid mediators regulate pulmonary fibrosis: potential mechanisms and signaling pathways
.
Int J Mol Sci.
2020
;
21
(
12
):
4257
.
32.
Paczesny
S
,
Hakim
FT
,
Pidala
J
, et al
.
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2014 Biomarker Working Group Report
.
Biol Blood Marrow Transplant.
2015
;
21
(
5
):
780
-
792
.
You do not currently have access to this content.

Sign in via your Institution